Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Catenin alpha-3 (CTNNA3) is a member of the vinculin/alpha-catenin family that functions as a core component of adherens junctions, facilitating cell-cell adhesion by linking the cadherin/β-catenin complex to the actin cytoskeleton[2][3][5]. It is highly expressed in the heart, peripheral nerves (especially Schwann cells), and oligodendrocytes of the central nervous system, playing critical roles in maintaining the structure of cardiomyocyte junctions and neuroglial adherens junctions[1][2]. CTNNA3 is implicated in the pathogenesis of multiple diseases, including arrhythmogenic right ventricular dysplasia (particularly the familial 13/biventricular variant), various neurodevelopmental and neurodegenerative disorders, asthma, and certain cancers, likely through its regulation of cell adhesion and tissue integrity in both cardiac and neural systems[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Catenin alpha-3 (CTNNA3).